-
Enhertu for HER2-Low and -Ultralow Metastatic Breast Cancer
Enhertu for HER2-Low and -Ultralow Metastatic Breast Cancer Dec 12, 2024 Dr. Aditya Bardia discusses Enhertu for metastatic hormone receptor-positive, HER2-low and -ultralow breast cancer and explains those terms. At the 2024 San Antonio Breast Cancer Symposium, Dr. Aditya Bardia, director of the Breast Oncology Program…
-
Enhertu Beats Chemotherapy for HER2-Low and -Ultralow Metastatic Breast Cancer
Enhertu Beats Chemotherapy for HER2-Low and -Ultralow Metastatic Breast Cancer Jun 17, 2024 Enhertu seems better than chemotherapy for metastatic breast cancers with even the lowest detectable levels of HER2. Read more…
-
Enhertu Beats Chemotherapy for HER2-Low and -Ultralow Metastatic Breast Cancer
Enhertu Beats Chemotherapy for HER2-Low and -Ultralow Metastatic Breast Cancer Jun 17, 2024 Enhertu offers better survival than chemotherapy for pre-treated, metastatic, HER2-low or -ultralow breast cancer. Read more…
-
HER2 negative but actually a low positive and neratinib
I'm making a list of questions for my oncologist appointment coming up and in looking at posts relative to metformin I came across neratinib. I realize the metformin trial ended up demonstrating that it was not beneficial in lessening recurrence rates. But apparently neratinib trials were because it was approved by the FDA…